Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Conexeu Sciences Inc.
Conexeu Sciences Inc. filed a Form D with the SEC on October 21, 2026, regarding an exempt offering of securities. The filing pertains to the company's capital raising activities, though specific terms and the total amount of the offering were not disclosed.…more
Conexeu Sciences Inc.
Conexeu Sciences raised capital through the issuance of 4,741,660 shares of common stock between September 14 and October 15, 2026, via private placements and warrant exercises. On October 15, 2026, the company raised $3,999,999 by issuing 1,333,333 units at $3.00 per unit, while an additional 83,334 units for management and directors remain in escrow pending shareholder approval. This issuance results in dilution for existing shareholders, and the company is obligated to file an S-1 registration statement for the resale of these securities.…more
Conexeu Sciences Inc.
Conexeu Sciences completed a private placement on October 15, 2026, raising $3,999,999 through the issuance of 1,333,333 units at $3.00 per unit. The company also secured additional funding through a $250,002 issuance to management and directors, pending shareholder approval, and a $750,000 special warrant issuance. These transactions will result in share dilution, and the company is committed to filing an S-1 registration statement for the resale of these securities.…more
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Conexeu Sciences Secures $5 Million in Private Placement
Conexeu Sciences has closed a $5 million private placement to fund manufacturing scale-up and regulatory testing for its medical device platform. The capital supports the company's goal to submit an FDA 510(k) application in the first quarter of 2027.…more
●●●●●●●● ●●●●● ●●●●●●
Conexeu Sciences is advancing its 'Ten Minute Tissue' wound care device toward a planned FDA 510(k) submission in the first quarter of 2027. The company has successfully scaled up manufacturing processes and is currently conducting the regulatory testing required for commercialization.…more
●●●●●●●● ●●●●● ●●●●●●
Preclinical-stage biotech company Conexeu Sciences will participate in several investor conferences throughout September and October. These events serve as opportunities for management to engage with stakeholders regarding the company's progress, though no specific commercial agreements were announced.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.